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Laboratory diagnosis of influenza is critical to its treatment and surveillance. With the emergence of novel 
and highly pathogenic avian influenza viruses, the role of the laboratory has been further extended to include 
isolation and subtyping of the virus to monitor its appearance and facilitate appropriate vaccine development. 
Recent progress in enhancing testing for influenza promises to both improve the management of patients 
with influenza and decrease associated health care costs. The present review covers the technological char­
acteristics and utilization features of currently available diagnostic tests, the factors that influence the selection 
of such tests, and the developments that are essential for pandemic preparedness.
Influenza virus belongs to the virus family Orthomyxo- 
viridae, which includes the genera Influenzavirus A, In- 
fluenzavirus B, and Influenzavirus C, the former 2 of 
which cause most hum an infections. Influenza A vi­
ruses naturally infect humans, as well as such animals 
as birds, pigs, and horses, and they generally cause yearly 
epidemics and, potentially, pandemics. Infections with 
influenza B virus are generally restricted to humans and 
cause epidemics more rarely. Influenza A viruses, which 
are characterized by the antigenicity of their nucleocapsid 
and matrix proteins, are further classified into 16 H and 
9 N subtypes according to their membrane glycoproteins 
(hemagglutinin [HA] and neuraminidase [NA]) and, fi­
nally, are identified as strains, such as the A/California/ 
7/2004 strain, according to the time and place of their 
first isolation fl, 2]. The predominant influenza virus 
subtypes known to circulate among humans are H1N1, 
H2N2, and H3N2, but infection with novel subtypes has 
been documented as causing outbreaks associated with 
different clinical manifestations, including severe respi-
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ratory illness (H5N1), conjunctivitis (H7N7 and H7N3), 
and common influenza-like symptoms (H9N2) [3]. The 
potential for both common and novel subtypes to cause 
infection in humans underscores the importance of es­
tablishing a definitive laboratory diagnosis of influenza.
LABORATORY DIAGNOSIS 
OF INFLUENZA
Laboratory diagnosis of influenza has become a cor­
nerstone of the prevention, containment, surveillance, 
and treatment of the associated illness. The emergence 
of novel, highly pathogenic avian influenza viruses, 
such as H5N1, has extended the role of the laboratory 
to include isolation and subtyping of the virus for dis­
ease surveillance and vaccine development. Because 
other respiratory viruses that cause similar nonspecific 
symptoms frequently cocirculate during influenza ep­
idemics, establishing a diagnosis of influenza on the 
basis of the clinical presentation alone is problematic, 
with reported sensitivity ranging from 38% (for chil­
dren) to 77% (for adults) [4, 5].
Laboratory testing for influenza has historically been 
of questionable value for the management of patients 
with influenza, because of limited test sensitivity, long 
turnaround times, and a lack of effective antiviral ther­
apies. The development of more rapid and accurate 
tests for the detection of influenza now enables the 
laboratory to provide a prompt, definitive diagnosis, 
which allows clinicians to initiate antiviral therapy, limit
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the injudicious use of antibacterials, implement appropriate 
infection-control measures, decrease the duration of hospital­
ization, reduce ancillary testing, and decrease health care costs 
[6- 8]. The present review describes the technological charac­
teristics and utilization features of currently available diagnostic 
tests for influenza, with emphasis given to the use of such tests 
in the appropriate clinical context.
CURRENT DIAGNOSTIC TESTING OPTIONS
Laboratory diagnosis of influenza can be accomplished by the 
detection of (1) the virus or (2) the patient’s imm une response 
to the virus. Diagnostic approaches for the identification of the 
virus include viral isolation, detection of viral antigen by im- 
munospecific assays, such as immunofluorescence microscopy, 
point-of-care (POC) testing (e.g., EIA or optical immunoassay), 
and detection of viral nucleic acid by use of amplification tech­
niques (i.e., nucleic acid testing [NAT]). Antibody detection is 
usually accomplished by virus neutralization (virus NT) and 
hemagglutination inhibition (HI) tests conducted to m onitor 
seroconversion to a specific virus strain or to determ ine im ­
mune status, for example, after vaccination [3, 9, 10].
Because laboratory tests for the diagnosis of influenza have 
limitations that can produce misleading results, their findings 
should be interpreted in conjunction with the clinical history 
of the patient. False-negative findings may occur because of 
low quantities of the viral analyte; inappropriately collected, 
handled, and/or transported specimens; the presence of viral 
inhibitors; and the emergence of novel subtypes for which the 
tests are not sensitive or specific. False-positive laboratory find­
ings can result from laboratory error, both  clerical and oper­
ational, and from suboptimal specificity of the test in question. 
Table 1 summarizes the advantages and disadvantages of in­
dividual tests.
Rapid Antigen (POC) Tests
Diagnosis of influenza by EIA has led to the development of 
easy-to-use, self-contained diagnostic kits that can provide re­
sults well within 1 h of the time of specimen collection. The 
World Health O rganization has issued recom m endations for 
the use of such kits [24]. Approval for some of these assays 
has been waived by the Clinical Laboratory Improvement 
A m endm ent, allowing for their use outside certified labora­
tories in POC settings. On-site diagnosis of influenza by POC 
tests has been shown to limit antimicrobial adm inistration, 
requests for blood culture, and the use of chest radiography, 
and it ultimately has been shown to reduce patient costs [8]. 
Currently, most POC tests distinguish influenza A virus from 
influenza B virus, but their role in the identification of avian 
influenza virus subtypes is unclear, because most claims of 
detection of novel subtypes have yet to be confirmed in clinical
studies. Table 2 describes the characteristics of representative 
POC tests.
The types of specimens used for POC testing, in decreasing 
order of sensitivity, are nasopharyngeal aspirates, nasopharyn­
geal swabs/washes, and throat swabs. The timing of specimen 
collection in relation to the onset of symptoms influences spec­
imen sensitivity. Optimal sensitivity is achieved when specimens 
are collected within the first few days of illness, because viral 
shedding peaks within 48 h of the onset of symptoms, with 
children having the highest viral titers for the longest duration. 
In general, POC tests are contraindicated for patients who have 
had symptoms for >3 days.
Overall, POC tests vary greatly in their sensitivity and spec­
ificity. The reported ranges of sensitivity (57%-90%) and spec­
ificity (65%-99%) are influenced by the study population, the 
type of specimen, and the time of collection after presentation 
[39]. Detection of influenza after recent im m unization with 
live attenuated viral vaccine, such as FluMist (M edlm m une 
Vaccines), can confound a diagnosis [11]. Direct comparison 
of the sensitivity and specificity of multiple POC tests is chal­
lenging, because evaluations have been performed under var­
iable conditions. Because the overall sensitivity of POC tests is 
lower than the overall sensitivities of immunofluorescence mi­
croscopy and isolation in cell culture, it is im portant that phy­
sicians who use POC tests have access to a reference laboratory 
to resolve ambiguous results and to ensure quality [5]. The 
clinical usefulness of these tests is associated with their positive 
and negative predictive values and is greatest during the peak 
influenza season, when false-positive results are less likely and 
the positive predictive value is high. Patients with a high pretest 
probability of infection and a negative POC result should un­
dergo further laboratory testing. When influenza activity is low, 
false-positive results are likely, the positive predictive value is 
low, and the negative predictive value is high. Outside of the 
influenza season, POC tests must be used with caution, and 
their results must be confirmed by other tests [40, 41],
Immunofluorescence Microscopy
Detection of influenza virus by immunofluorescence micros­
copy, which is referred to as a “direct fluorescent antibody” 
(DFA) test or an “immunofiuorescent antibody” (IFA) test, was 
first developed in the 1960s, and it remains a valuable method, 
despite its relatively extensive infrastructure requirements [13]. 
The DFA technology involves deposition of respiratory epithe­
lial cells onto a welled slide, followed by staining with specific 
antibodies directly conjugated to a fluorescent dye. After drying 
and fixation, a monoclonal antibody conjugate is applied to 
slide wells and is incubated and washed before examination by 
fluorescence microscopy. Its sensitivity and specificity rely on 
the presence of an adequate num ber of infected cells, and they 
can vary according to specimen type. IFA technology involves
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Table 1. Technologies used in diagnostic influenza tests and their associated characteristics.
Technology In-house or commercial test
Laboratory
requirement(s)
Time to  
final result Advantage(s) Disadvantage(s) Reference(s)
Im m unospecific assay for viral 
antigen detection
Rapid antigen test M ultip le commercial tests'3 BSL-2 (for HPAIV only) <30 min Fast; requires minimal technical exper­
tise; requires m inimal infrastructure; 
POC setting
Sensitivity is less in adults; speci­
fic ity  is suboptimal outside of 
the influenza season; cannot 
distinguish between H sub­
types (e.g., H1, H3, and H5); 
sensitivity for HPAIV unknown
[5. 11. 12]
Im m unofluorescence m icroscopyb Commercial monoclonal antibody 
for influenza A and B viruses; 
noncommercial monoclonal 
antibody specific for H1,
H3, H5, H7, and H9
BSL-2 for specimen 
preparation of 
HPAIV
- 1 - 4  h Fast and versatile; simultaneous 
diagnosis o f m ultiple and alternative 
respiratory viruses; sensitiv ity greater 
than that of POC tests; detects viable 
and nonviable virus; identification of 
specific H subtypes in developm ent
Currently cannot distinguish be­
tw een H subtypes; requires 
technical expertise; requires 
fluorescence microscope; 
sensitivity for HPAIV unknown
[13. 14]
Nucleic acid testing '' Commercial kits available for 
detecting influenza A and B 
viruses; H5N1 sequences 
now  publicly available
BSL-2 for sample 
preparation of 
HPAIV
4 -6  h Highly sensitive (detects 1 —10 infectious 
units); detects viable and nonviable 
virus; potential for high throughput
Requires technical expertise; 
primers may require updating 
because of antigenic drift, 





Conventional culture BSL-2; certified BSL-3 
for HPAIV
3 -1 4  days Highly sensitive (-1 0  pfu/mL); provides 
viable virus for subtyping and anti­
viral resistance testing; detects all 
influenza A and B virus types, 
including HPAIV; detects other 
respiratory viruses
Delay in receiving results; 




Shell vial cultured Commercial reagents available BSL-2; certified BSL-3 
for HPAIV
18-48 h Faster than conventional culture; detects 
all influenza A and B virus types, 
including HPAIV; detects other 
respiratory viruses
Virus may be nonviable, 
making passage difficult; 









Cell culture equipm ent Several w eeks needed to
fo r virus NTs; BSL-2 
fo r epidem ic virus 
and BSL-3 for 
pandemic virus
HI equipm ent, plates, 
and diluters
In-house assays using commer­
cially available anti-hum an 
antibody conjugates
Commercial reagents difficult 
to  locate
obtain paired serum 
samples; a single 
convalescent-phase 
serum sample may 
confirm  infection w ith  
novel subtypes 
Several w eeks needed to 
obtain paired serum 
samples; a single 
convalescent-phase 
serum sample may 
confirm  infection w ith  
novel subtypes 
Several w eeks needed to 
obtain results fo r paired 
serum samples; a single 
convalescent-phase 
serum sample may 
confirm  infection w ith  
novel subtypes 
Several w eeks needed to 
obtain results fo r paired 
serum samples
Highly specific and sensitive; may 
be superior fo r HPA1V strains
Labor intensive and tim e 
consuming
[211
Simpler than NT but w ith  equivalent sensitiv ity Labor intensive; tim e  consuming; 
suboptimal for HPA1V, {except if 
horse RBCs are used)
[10, 22]




to  influenza A  and B viruses
Time consuming and seldom 
perform ed; likely inadequate 
fo r HPA1V
[10, 22]
NOTE. BSL, biosafety level; DFA, direct fluorescent antibody test; HI, hemagglutination inhibition; HPA1V, highly pathogenic avian influenza virus; NT neutralization test; POC, point of care; RBCs, red blood cells; RT-PCR, 
reverse-transcription polymerase chain reaction. 
a See table 2. 
b DFA or 1FA.
RT-PCR and nucleic acid sequence-based amplification.
Single cell line and m ixed cell line; enable cultivation of o ther respiratory viruses.
Table 2. Examples of specific rapid antigen tests.
Name of tes t (manufacturer) Basis of technology Influenza virus(es) detected Sensitivity,' % S pecific ity,' % Laboratory requirement(s) Reference(s)
Directigen Flu A (Becton-Dickinson) EIAb A (including H5N1, H7N2, and H7N3) 24-78 91.6 Certification [5, 25-28]
Directigen Flu A+B (Becton-Dickinson) EIAb A and B distinguishes between the tw o 44-85 99.74 Certification [5, 25, 27, 28]
-LU OIA (Thermo Electron) OIAb A and B does not distinguish between the tw o C C Certification [25, 29-32]
-LU OIA A/B (Thermo Electron) OIAb A and B distinguishes between the tw o 88.4d 69.4e Certification [5, 25]
XPECT Flu A&B (Remel) Lateral f lo w b A and B distinguishes between the tw o 94.4 Certification [5, 25]
NOW  Influenza A&B (Binax) EIAb A and B distinguishes between the tw o 75*; 50° 100h Certification [5, 33, 34]
QuickVue influenza test (Quidel) Lateral flo w A and B does not distinguish between the tw o C C CLIA waived; may be perform ed in an 
office that requires waiver or certification
[5]
QuickVue influenza test A&B (Quidel) Lateral flo w A and B; distinguishes between the tw o 70-95 82.6-98 CLIA waived; may be perform ed in an 
office that requires waiver or certification
[5, 25, 29, 35-37]
ZstatFlu (ZymeTx) Chem ilum inescence1 A and B; does not distinguish between the tw o 65-88 83-92 CLIA waived [5, 36, 38, 39]
NOTE. CLIA, Clinical Laboratory Im provem ent A m endm ent; OIA, optical imm unoassay. 
a Com pared with viral isolation. 
b Nucleoprotein.
c Not a s s e s s e d  in peer-review ed literature. 
d For influenza A virus in nasal aspirates. 
e For influenza B virus in nasal aspirates. 
f For influenza A virus.
3 For influenza B virus. 
h For influenza A and B viruses.
1 Neuraminidase.
Figure 1. Cytopathic effect in Madin-Darby canine kidney cell cultures at 0, 24, and 48 h after infection
staining dried, fixed cells with a monoclonal antibody to the 
respective viruses and then with an antibody conjugate to a 
mouse immunoglobulin. IFA provides greater consistency when 
testing for multiple respiratory viruses is done, because only a 
single conjugate is used, regardless o f the num ber of virus- 
specific monoclonal antibodies used. IFA usually is more sen­
sitive than DFA, but the latter is more popular because of its 
shorter turnaround time, and both tests allow simultaneous 
detection of other respiratory viruses (e.g., respiratory syncytial 
virus, parainfluenza virus, and adenovirus) [14], However, the 
ability o f commercial monoclonal antibodies to detect avian 
influenza virus subtypes has not been well described, and they 
cannot be recommended at this time. Although not commer­
cially available, monoclonal antibodies specific for H I, H3, H5, 
and H7 can be obtained and will prove to be invaluable for 
subtype identification when multiple H subtypes are cocircu- 
lating [42]. Overall, DFA is a valuable diagnostic test for in­
fluenza because it provides fast, relatively accurate results and 
it is an excellent choice for confirming POC test findings.
Virus Isolation: Culture Techniques
Influenza virus was first isolated in 1933, by inoculation of 
specimens into the amniotic cavity of 10- 12-day-old ernbryo-
nated chicken eggs. Although high yields o f virus can be har­
vested after 3 days of incubation, this approach is no longer 
routinely used in the diagnosis o f influenza. It is, however, used 
by reference laboratories to achieve a high sensitivity for de­
tection and to obtain high-titer virus stocks [1].
C o n ven tio n a l cu lture . The tim e-honored technique of 
conventional culture, introduced in the 1940s, involves inoc­
ulation of the patient specimen into a cell culture that is then 
m onitored for the development of cytopathic effect, for m an­
ifestation of hemadsorption after the addition of erythrocytes, 
or for the presence of influenza antigen, as demonstrated by 
specific antibody staining, shown in figure IB and 1C, figure 
2A, and figure 3, respectively. The development o f cytopathic 
effect, however, can be caused by a number of respiratory vi­
ruses, and the cytopathic-effect characteristic o f influenza may 
not always be observed in infected cell lines; hence, viral in­
fection must be confirmed by immunofluorescence microscopy 
or by hemadsorption performed using guinea pig erythrocytes 
[17]. Immunofluorescence microscopy is also used to identify 
the isolated virus as influenza A or B virus [17]. Virus isolation 
is effective only if the cell culture system is sensitive to the 
inoculated virus, and not all host cells are universally permissive 
to all influenza A viruses [16]. Isolation of influenza A and B
Figure 2. A, Presence of hemadsorption in rhesus monkey kidney (RhMK) cells. B, Absence of hemadsorption in RhMK cells.
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viruses and other respiratory viruses is conventionally per­
formed on monolayers of either primary cell cultures, such as 
rhesus monkey kidney (RhMK) or African green monkey kid­
ney (AGMK) cells, as well as established cell lines, including 
Madin-Darby canine kidney (MDCK), mink lung epithelial cell 
line (MvlLu), rhesus monkey kidney (LLC MK2), and buffalo 
green monkey kidney (BGMK). MDCK cells are especially use­
ful for isolation of influenza B virus, and M vlLu cells have 
been reported to be more sensitive than MDCK or RhMK cells 
for rapid detection of influenza virus in culture [43, 44].
R ap id  shell vial culture. Shell vial culture uses single or 
mixed cell lines and has the unique feature of enhancing sen­
sitivity and shortening the time to detection through enhancing 
the viral infectivity of the cells by centrifugation. Detection of 
other respiratory viruses can be facilitated by using monolayers 
of 2 different cell types in a single vial (e.g., R-Mix). Diagnosis 
by shell vial culture is more rapid than diagnosis by conven­
tional culture (time to diagnosis, 24 h vs. >3 days), with 
sensitivity equivalent to that of conventional tube cultures and 
greater than that of DFA [18-20], Although cell lines used for 
seasonal influenza also support the growth of highly pathogenic 
avian influenza viruses, isolation of these viruses is restricted 
to appropriately certified biosafety level 3 (BSL-3) laboratories. 
Figure 1 shows the presence and absence of cytopathic effect 
in MDCK cell cultures; figure 2, the presence and absence of 
hemadsorption in RhMK cells; and figure 3, positive fluorescent 
staining for influenza virus in R-Mix culture.
NAT
The most common NAT used for the diagnosis of influenza is 
the reverse-transcription polymerase chain reaction (RT-PCR) 
assay, but nucleic acid sequence-based amplification has been 
used effectively as well. These are considered to be the most
sensitive, specific, and versatile tests for the diagnosis of influ­
enza and are replacing viral isolation as the reference standard
[15]. Once viral RNA is extracted from the specimen, it can 
be used in RT-PCR not only to identify the virus as influenza 
but, also, to further determine the subtype and even the strain 
by sequence analysis. The viral genotype can be readily deter­
mined by sequencing some or all of the viral genes, although 
genotyping of the virus directly from patient specimens often 
requires some level o f amplification in cell culture. Most RT- 
PCR assays for influenza A and B viruses use primers com­
plementary to the relatively stable gene 7, which encodes the 
conserved matrix protein, and can successfully detect all viral 
strains observed to date [16]. HA-specific RT-PCR with primers 
targeting gene 4 allows identification of the H subtype of in­
fluenza A virus.
Compared with isolation in cell culture, sensitive PCR assays 
can m ore readily identify influenza viruses in im m unosup- 
pressed transplant recipients and persons with chronic lung 
diseases for whom frequent lower respiratory tract infections 
are often associated with low viral levels. Rapid, accurate iden­
tification of respiratory pathogens in these vulnerable popu­
lations is critical to timely treatment and limitation of the nos­
ocomial spread of infection [45],
Serological Testing for Influenza
Serological tests, including virus NT, HI, complement fixation, 
EIA, and indirect immunofluorescence microscopy, are based 
on the presence of influenza-specific antibodies that first appear 
~2  weeks after initial infection and that reach peak levels 4-7 
weeks after initial infection. These tests are not widely available 
and are rarely used for patient management, but they may be 
indicated for retrospective diagnosis of and disease surveillance 
for novel subtypes [2], A 2=4-fold increase in the influenza 
antibody titers noted between the acute-phase and convales- 
cent-phase (3-4 weeks after initial infection) serum samples 
obtained from patients is diagnostic of infection. In adults who 
have sustained multiple influenza virus infections, increases in 
the strain-specific antibody titer must be interpreted with cau­
tion, because a response to the infecting virus strain may be 
accompanied by parallel responses to previously encountered 
strains [46]. However, in patients infected with a novel subtype, 
detection of its specific antibody is diagnostic. Finally, serolog­
ical testing allows for quantification of responses to influenza 
vaccination, even though those responses often are not as robust 
as those resulting from virus infection [22],
Virus NT. The NT is the definitive serological method of 
identifying a specific strain of influenza virus or antibody to 
this virus, and it is particularly useful for the identification of 
highly pathogenic avian influenza viruses [42]. Because the test 
involves the use of infectious virus, its use is restricted to ap­
propriately certified BSL-3 laboratories when these avian viruses
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are handled. In this assay, 100 infectious units of test virus are 
added to serial dilutions of the serum, and, after incubation, 
the mixtures are applied to respective cell monolayers, which 
are then monitored for cytopathic effect. As the antibody be­
comes diluted below the level of protection, viral growth be­
comes detectable [21, 47].
H I assays. These are labor-intensive and time-consuming 
assays that require several controls for standardization. Their 
advantages include inexpensive, readily available reagents; sen­
sitivity greater than that associated with complement fixation; 
and high specificity in identifying strains [48]. HI is used to 
determ ine the im m une response to influenza in surveillance 
and vaccine studies [10, 22]. The technology involves the ad­
dition of 4 hemagglutinating units of virus to serial dilutions 
of serum; incubation; and, finally, the addition of washed 
chicken, turkey, human, or guinea pig erythrocytes to each di­
lution [47]. The highest dilution of serum that inhibits hem ­
agglutination is designated as the HI titer. HI may not be as 
sensitive as NT for the detection of an im m une response to 
avian influenza viruses, but reference laboratories have reported 
enhanced sensitivity with horse erythrocytes [49]. W hen the 
isolates are typed, the reference antisera to a number of strains 
m ust be included, because strains may differ by only one or 
more epitopes. The reference antiserum  with the highest HI 
titer identifies the strain of the isolate [17]. Titers of at least 1: 
40 or serum neutralizing titers of 3=1:8 have been associated 
with protection.
C om plem en t fixa tio n . This test measures the antibody re­
sponse to nucleoprotein, conserved among influenza A virus 
strains [17]. It has been mostly supplanted by more time-ef­
ficient EIAs, for which reagents are more readily available [10].
EIA. EIA is used largely for investigational studies, although 
EIA and Western blot analysis have been shown to be effective 
in detecting an imm une response to avian influenza in children 
[17, 23]. Testing for antibody to influenza by use of these type- 
specific approaches is perform ed mainly by in-house assay, 
because commercial kits have yet to be well validated. Age- 
matched negative control serum samples, which may be dif­
ficult to locate, are necessary to establish the appropriate signal- 
to-noise ratio.
FACTORS INFLUENCING THE SELECTION 
OF TESTS
Test selection is governed by multiple factors outlined in table
3. The size and capacity of the laboratory have a major impact. 
Small laboratories associated with physician offices or small 
hospitals are usually restricted to the use of rapid POC tests, 
which require minimal infrastructure and can be performed by 
staff with limited knowledge of virology. Their comparatively 
high cost per test is compensated by low infrastructure ex­
penses. Despite the seeming simplicity of Clinical Laboratory
Improvement Amendment-waived testing, health care person­
nel must be vigilant about good laboratory practices, undergo 
adequate training, have access to quality control testing, and 
be appropriately supervised [41].
Large hospital and reference laboratories that are staffed with 
trained technologists have many options for influenza testing, 
including the use of POC tests. DFA, with its higher sensitivity 
and potentially lower associated cost per test, is often most 
appropriate in these settings. Isolation in cell culture is generally 
used as a reflex test after a negative DFA result, as a confir­
matory test for quality assurance, or to amplify the virus for 
additional subtyping or resistance testing. The HI test may be 
used to m onitor seroconversion and to subtype viral isolates. 
Increasingly, large laboratories are adopting nucleic acid-based 
technologies for the diagnosis of influenza and infection with 
other respiratory pathogens. Its implementation requires com­
plex, expensive infrastructure; highly trained technologists; and 
space that minimizes amplicon contamination. Simpler and less 
expensive platforms for the nucleic acid-based diagnosis of 
influenza are currently under development.
INFLUENZA TESTING DURING A PANDEMIC: 
LABORATORY DEMANDS AND ANTIVIRAL 
SUSCEPTIBILITY TESTING
Laboratory demands for influenza testing will most likely in­
crease substantially in the prepandemic stages and be com ­
pounded in early pandemic stages by the need for appropriately 
certified BSL-3 laboratory facilities. In pandemics, rapid d i­
agnosis requires adequate surge capacity. NAT, accompanied by 
high-volume automated nucleic acid extraction, can be scaled 
up without a proportional demand on the technologist’s time. 
More important, the RT-PCR assay can be used initially to 
detect all influenza viruses and subsequently can be reflexed to 
a more specific RT-PCR assay with HA-specific primers for the 
identification of a pandemic strain. Last, NAT is the least likely 
approach to be adversely affected by supply problems in the 
event of increased demands during a pandemic; except for 
primers and probes, virtually all reagents have broad applica­
tions and are readily available.
The maximum burden on the laboratory is likely to occur 
during pandemic stage 4, when the virus has evolved to allow 
hum an-to-hum an transmission but its clinical profile is not yet 
well established. During this stage, clinicians will likely rely 
heavily on laboratories to rule out avian influenza viruses in 
patients presenting with respiratory symptoms, especially dur­
ing the winter months, when seasonal epidemic influenza virus 
strains are cocirculating. Under these circumstances, the lab­
oratory will not have a strong basis for triage and, hence, will 
be required to process increasing numbers of specimens.
Demands for laboratory testing and testing algorithms may 
change as the pandemic evolves. Possible testing algorithms for
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Table 3. Factors that influence selection of test.
Test Specimen type
Duration of specimen 
acceptability8 M ost appropriate patients
M ost appropriate 
laboratory setting
Level of influenza virus 
activity detected Laboratory requirement(s) Reference(s)
Rapid antigen tests 
(POO
NP swab, throat swab, 
NP wash, and nasal 
aspirate
<72 h All, especially children w ho  have higher 
viral titers; patients w ith  a high 
pretest probability of infection; 
travelers from  areas of endemicity; 
patients w ith  link to  outbreaks
Office-based clinics; small 
laboratories; large 
laboratories outside 
of the influenza season
Epidemic and sporadic; 
some tests are 
effective for 





NP swab or wash, 
bronchial wash, 
and nasal and 
endotracheal 
aspirates
Best at <72 h All Larger laboratories, includ­
ing hospital, academic, 
reference, and public 
health laboratories
Sporadic and epidemic; 
pandemic, if reagents 
are available
BSL-2 [13, 50)
Viral cu lture0 NP swab, throat swab, 
NP or bronchial wash, 
NP and endotracheal 
aspirate, 
and sputum
Best at <72 h; acceptable 
for sym ptom atic patients 
for >72 h
All; acceptable for patients 
w ith  decreasing levels of viral 
shedding
Hospital, academic, refer­
ence, and public health 
laboratories; only labora­
tories w ith  appropriate 
BSL-3 certification for 
pandemic strains
Sporadic and epidemic; 
pandemic only in 
certified BSL-3 
laboratories
BSL-2 laboratories for 
sporadic and epidemic 
influenza; BSL-3 labora­




NAT'1 NP swab, throat swab, 
nasal or bronchial 




Best at <72 h; acceptable 
for sym ptom atic patients 
at s 7 2  h
All; acceptable for patients 
w ith  decreasing levels of viral 
shedding
Hospital, academic, refer­
ence, and public health 
laboratories
Sporadic, epidemic, and 
pandemic
BSL-2 [15, 45, 51)
HI and virus NT W hole-blood specimens; 





at presentation of 
illness; convalescent- 
phase specimens 2-3 
w eeks later
Outbreak investigations Public health, academic, 
and reference 
laboratories
Sporadic, epidemic, and 
pandemic
HI: BSL-2; Virus NT: BSL-3 [17)
NOTE. BSL, b iosafety level; HI, hemagglutination inhibition; HPAIV, highly pathogenic avian influenza virus; NAT nucleic acid testing; NR nasopharyngeal; NX neutralization test; POC, point o f care. 
B From the onset of sym ptom s. 
b See table 2. 
c Conventional or shell vial.
d Reverse-transcription polymerase chain reaction and nucleic acid sequence-based amplification.
Figure 4. A, Possible testing algorithm during early pandemic stages. B, Possible testing algorithm during late pandemic stages. BSL, biosafety 
level; DFA, direct fluorescent antibody test; RT-PCR, reverse-transcription polymerase chain reaction.
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early- and late-stage pandemic periods are shown in figure 4. 
Physicians will likely rely less on laboratory diagnosis as the 
unique clinical features of infection with the pandemic strain 
become apparent. However, there may be an increase in the 
demand for serological confirmation of influenza and evidence 
of immunity, as well as for testing for resistance to antiviral 
drugs, such as M2 and the NA inhibitors. As the pandemic 
progresses, documentation of imm unity from a mild form of 
infection could be used to determ ine the need for antiviral 
drugs for individuals, such as medical personnel, who are work­
ing under a high risk of infection and are vital to the delivery 
of health care.
The susceptibility of a virus isolate to antiviral agents can be 
established by genotypic and phenotypic testing [52], Testing 
for resistance to amantadine is currently accomplished by se­
quence analysis of the M2 open reading frame. Specific m u­
tations in the NA gene have been shown to correlate with 
resistance to oseltamivir [52]. Although this approach can be 
applied to determine resistance to NA inhibitors, convention­
al inhibition assays in cell culture remain necessary, because 
knowledge of mutations leading to this resistance remains in­
complete. The chemiluminescent NA enzyme assay is currently 
being used to m onitor the appearance of clinical isolates that 
are resistant to zanamivir and oseltamivir [53]. However, com­
prehensive testing for antiviral resistance by use of inhibition 
of virus growth will likely be restricted to appropriately certified 
BSL-3 laboratories. Finally, assessment of the response to an 
NA inhibitor in very ill patients may be possible by determining 
the decrease in the viral load within days after initiation of 
treatment [52],
FUTURE DEVELOPMENT OF DIAGNOSTIC 
TESTS FOR INFLUENZA
Although our current diagnostic technologies are reasonably 
effective for sporadic and epidemic influenza, new develop­
ments are in progress to enhance diagnostic capability. Two 
new promising developments include technologies based on 
microarray chips and the Luminex X-Map. These methods are 
based on amplification of the viral genomic nucleic acid after 
hybridization to target probes, followed by monitoring by an 
automated reader [53, 54]. O ther new developments will most 
likely include more sensitive and more specific POC tests, which 
would provide real-time laboratory diagnosis in clinical prac­
tice, improving the management of both  sporadic cases and 
institutional outbreaks.
In the future, applications of microarray technologies will 
be expanded for NATs, providing same-day results for most 
respiratory viruses in larger laboratory settings [55]. The in ­
creasing use of genome sequence analysis is expected to allow 
more-rapid detection of new strains, which is critical both for
viral surveillance and  for th e  vacc ina tion -deve lopm en t p ro ­
gram . If POC tests can be developed to diagnose novel subtypes, 
they will play an im portan t role in a pandem ic setting. These 
new  developm ents prom ise to  im prove the m anagem ent o f 
sporadic and epidem ic influenza in  b o th  individual patients 
and  com m unities, as well as to  address the need for high- 
volum e testing in the event o f a pandem ic.
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